- Home
- CCK vs EXEL Comparison
CCK vs EXEL Comparison
Compare CCK & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCK
- EXEL
- Stock Information
- Founded
- CCK 1906
- EXEL 1994
- Country
- CCK United States
- EXEL United States
- Employees
- CCK N/A
- EXEL N/A
- Industry
- CCK Containers/Packaging
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCK Industrials
- EXEL Health Care
- Exchange
- CCK Nasdaq
- EXEL Nasdaq
- Market Cap
- CCK 11.3B
- EXEL 10.4B
- IPO Year
- CCK N/A
- EXEL 2000
- Fundamental
- Price
- CCK $100.02
- EXEL $42.96
- Analyst Decision
- CCK Strong Buy
- EXEL Buy
- Analyst Count
- CCK 14
- EXEL 24
- Target Price
- CCK $118.57
- EXEL $44.73
- AVG Volume (30 Days)
- CCK 1.6M
- EXEL 3.2M
- Earning Date
- CCK 10-20-2025
- EXEL 11-04-2025
- Dividend Yield
- CCK 1.05%
- EXEL N/A
- EPS Growth
- CCK 888.69
- EXEL 53.55
- EPS
- CCK 8.10
- EXEL 2.38
- Revenue
- CCK $12,141,000,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- CCK $4.87
- EXEL $9.14
- Revenue Next Year
- CCK $2.88
- EXEL $12.51
- P/E Ratio
- CCK $12.24
- EXEL $17.42
- Revenue Growth
- CCK 3.27
- EXEL 9.93
- 52 Week Low
- CCK $75.98
- EXEL $31.90
- 52 Week High
- CCK $109.48
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- CCK 61.35
- EXEL 66.29
- Support Level
- CCK $95.07
- EXEL $39.83
- Resistance Level
- CCK $100.44
- EXEL $41.55
- Average True Range (ATR)
- CCK 2.30
- EXEL 1.46
- MACD
- CCK 0.28
- EXEL 0.45
- Stochastic Oscillator
- CCK 87.14
- EXEL 99.14
About CCK Crown Holdings Inc.
Crown Holdings is one of the world's largest producers of metal packaging. The company manufactures beverage cans, metal food cans, and closures as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.